Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy
2017 · Journal of Clinical Investigation · 310 citations
https://doi.org/10.1172/jci89455
K
Kevin Sek
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
67
Papers
2.4K
Citations
13
h-index
14
i10-index
Kevin Sek is an academic researcher from The University of Melbourne. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Immunotherapy and Immune Responses & Immune cells in cancer. The author has an h-index of 13, co-authored 57 publications.
ORCID: 0000-0003-4634-7600Papers by this author
worksCRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy
2021 · Nature Communications · 199 citations
https://doi.org/10.1038/s41467-021-23331-5
FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy
2024 · Nature · 185 citations
https://doi.org/10.1038/s41586-024-07242-1
CRISPR-Cas9 screening identifies an IRF1-SOCS1-mediated negative feedback loop that limits CXCL9 expression and antitumor immunity
2023 · Cell Reports · 8 citations
https://doi.org/10.1016/j.celrep.2023.113014
CRISPR-Cas9 screening identifies an IRF1-SOCS1-mediated negative feedback loop that limits CXCL9 expression and antitumor immunity
2024 · Cell Reports · 3 citations
https://doi.org/10.1016/j.celrep.2024.113793
Refuel and endure: improving metabolic fitness and efficacy in CAR-T therapy
2026 · Immuno-Oncology Technology · 0 citations
https://doi.org/10.1016/j.iotech.2026.101583
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat